Sacha Schermerhorn

Founder and CEO, Babylon Bio · Person · Healthcare

Mentions

Episodes

Claims

Sacha Schermerhorn - Founder and CEO, Babylon Bio. Tracked across 18 mentions in podcasts and expert conversations analyzed by Sonic.

What Sacha Schermerhorn has said

Sacha Schermerhorn theorizes that tau fibrils cause neurodegeneration in Alzheimer's not by their presence, but by sequestering essential proteins, leading to a loss of function.

neutral·Sacha Schermerhorn

Sacha Schermerhorn expects the clinical trial readout for Biogen's BIIB080 to be delayed from its slated May date to Q4 of this year due to recruitment difficulties.

neutral·Sacha Schermerhorn

Sacha Schermerhorn predicts that BIIB080, an intrathecally delivered tau ASO from Biogen and Ionis, will be the most efficacious drug for Alzheimer's to date.

bullish·Sacha Schermerhorn

Sacha Schermerhorn theorizes that tau fibrils cause neurodegeneration in Alzheimer's not by their presence, but by sequestering essential proteins, leading to a loss of function.

SpeculativeSacha SchermerhornApr 9

Sacha Schermerhorn expects the clinical trial readout for Biogen's BIIB080 to be delayed from its slated May date to Q4 of this year due to recruitment difficulties.

SpeculativeSacha SchermerhornApr 9

Sacha Schermerhorn predicts that BIIB080, an intrathecally delivered tau ASO from Biogen and Ionis, will be the most efficacious drug for Alzheimer's to date.

SpeculativeSacha SchermerhornApr 9

A study in Wales found that individuals who received the shingles vaccine were 20% less likely to develop Alzheimer's disease or all-cause dementia within a seven-year period.

Expert perspectiveSacha SchermerhornApr 9

The Alzheimer's drug Aducanumab reduced amyloid PET imaging signals by approximately 76% but showed no impact on patient cognition.

Expert perspectiveSacha SchermerhornApr 9

Approximately half of all research funding for Alzheimer's disease has been spent on the amyloid cascade hypothesis.

Expert perspectiveSacha SchermerhornApr 9

Trontinimab is an antibody therapeutic that hijacks the transferrin receptor to increase its transport across the blood-brain barrier, resulting in the best amyloid clearance efficacy seen to date.

Expert perspectiveSacha SchermerhornApr 9

Pfizer acquired Biohaven for $11.6 billion after Biohaven successfully developed Rimegepant, a migraine drug it had licensed from Bristol Myers Squibb.

Expert perspectiveSacha SchermerhornApr 9

Sacha Schermerhorn believes that fine-tuning will define the next decade of AI development.

SpeculativeSacha SchermerhornApr 9

An initial epidemiological study found that people taking sildenafil (Viagra) were 69% less likely to develop Alzheimer's, though follow-on studies were unable to reproduce this finding.

Expert perspectiveSacha SchermerhornApr 9

A 1991 study by Simon LeVay published in Science found that the third interstitial nucleus of the anterior hypothalamus is 2.8 times larger in heterosexual males than in homosexual males and women.

Expert perspectiveSacha SchermerhornApr 9

Babylon Bio was founded with the mission of finding a cure for Alzheimer's disease.

Official sourceSacha SchermerhornApr 9

Babylon Bio is collaborating with OpenAI to fine-tune models that can predict clinical trial outcomes, using the binary success or failure of trials as a loss function to train the models on biologica...

Expert perspectiveSacha SchermerhornApr 9

The FDA advisory committee for Biogen's Aducanumab, consisting of 14 members, unanimously rejected the drug's approval, yet it was still submitted for approval.

Expert perspectiveSacha SchermerhornApr 9

The biomarker p-tau217, a fragment of tau tangles, is the single most predictive marker for when an individual will develop the cognitive impairment phase of Alzheimer's disease.

Expert perspectiveSacha SchermerhornApr 9

Biomarker data indicates that amyloid plaques begin to deposit in the brain 20 to 30 years before the onset of Alzheimer's symptoms.

Expert perspectiveSacha SchermerhornApr 9

Only 0.1% of a monoclonal antibody therapeutic administered to a patient will cross the blood-brain barrier and enter the brain.

Expert perspectiveSacha SchermerhornApr 9

Babylon Bio's strategy involves acquiring and developing shelved pharmaceutical assets that could generate exits in the low nine-figure range to self-finance its primary Alzheimer's research.

Expert perspectiveSacha SchermerhornApr 9

Create a free account to see Sacha Schermerhorn's full intelligence report - every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail